Post by M. Hawbaker on Mar 17, 2021 21:37:08 GMT
Moderna, Inc. revealed on Tuesday that the first participants have been inoculated in a new study called KidCOVE that evaluates the company’s mRNA-1273 COVID-19 vaccine on pediatric patients six months old to twelve years old.
According to the press release, the study will involve two doses administered 28 days apart. Moderna expects to register over 6,700 pediatric children. The participants will be followed for one year after their second dose to assess overall vaccine safety, young body responses, and efficacy.
“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID and BARDA for their collaboration,” said Stéphane Bancel, Chief Executive Officer of Moderna.
“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID and BARDA for their collaboration,” said Stéphane Bancel, Chief Executive Officer of Moderna.
